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Although the herpes simplex virus type 1 (HSV-1) tegument is comprised of a large number of viral and
cellular proteins, how and where in the cell these proteins are recruited into the virus structure is poorly
understood. We have shown previously that the immediate-early gene product ICP0 is packaged by a mecha-
nism dependent on the major tegument protein VP22, while others have shown a requirement for ICP27. We
now extend our studies to show that ICP0 packaging correlates directly with the ability of ICP0 to complex with
VP22 in infected cells. ICP27 is not, however, present in this VP22-ICP0 complex but is packaged into the virion
in a VP22- and ICP0-independent manner. Biochemical fractionation of virions indicated that ICP0 associates
tightly with the virus capsid, but intranuclear capsids contained no detectable ICP0. The RING finger domain
of ICP0 and the N terminus of VP22 were both shown to be essential but not sufficient for ICP0 packaging and
complex formation. Strikingly, however, the N-terminal region of VP22, while unable to form a complex with
ICP0, inhibited its translocation from the nucleus to the cytoplasm. PML degradation by ICP0 was efficient in
cells infected with this VP22 mutant virus, confirming that ICP0 retains activity. Hence, we would suggest that
VP22 is an important molecular partner of ICP0 that controls at least one of its activities: its assembly into
the virion. Moreover, we propose that the pathway by which VP22 recruits ICP0 to the virion may begin in the
nucleus prior to ICP0 translocation to its final site of assembly in the cytoplasm.
The herpesvirus tegument is the virion compartment located
between the DNA-containing capsid and the virus envelope
(6). The tegument is the equivalent of the matrix of a range of
other enveloped viruses but is unusual in that it comprises a
very large number of proteins. A recent proteomic study of the
composition of herpes simplex virus type 1 (HSV-1) virions has
shown that at least 26 virus-encoded components are recruited
into the HSV-1 tegument (32). Some of these proteins, such as
VP1/2, VP13/14, VP16, and VP22, are classified as major,
structurally significant components (23, 44), while some, such
as vhs and the protein kinase UL13, are minor but nonetheless
important components (38, 42). In addition to virus-encoded
proteins, human cytomegalovirus (hCMV), Epstein-Barr virus
(EBV), Kaposi’s sarcoma-associated herpesvirus (KSHV), and
HSV-1 have all been shown to package a wide range of cellular
proteins into their teguments (25, 32, 49, 54).
It is proposed that after fusion of the virus envelope with the
cellular membrane, the contents of the tegument are released
into the cytoplasm of the cell. Hence, the tegument is believed
to deliver a range of factors involved in the initiation of virus
infection. The roles of a few tegument proteins, such as the
immediate-early (IE) gene transactivator VP16 and the host
shutoff protein Vhs, are well established at early stages of
infection (2, 29, 39, 41). A number of years ago, several studies
suggested that the IE protein ICP0 was also packaged into the
HSV-1 particle (50, 52), but these results have remained some-
what controversial, with the suggestion that the ICP0 detect-
able in HSV-1 virion preparations may be a consequence of
contamination. Evidence for specific ICP0 assembly into the
virus was strengthened by our own more recent studies, which
showed that while we could easily detect ICP0 in wild-type
(Wt) virus particles, it was not detected with virion prepara-
tions lacking the major tegument protein VP22, suggesting that
VP22 was somehow involved in the assembly of ICP0 (9). The
case for ICP0 as a virion component was further enhanced by
recent proteomic studies in which ICP0 was clearly identified
as a component of highly purified HSV-1 virions (32). None-
theless, a role for ICP0 at very early stages of infection prior to
IE gene expression is yet to be determined.
ICP0 has been characterized as a general transactivator of
gene expression and has recently been shown to dissociate the
genome silencing complex consisting of REST-CoREST-his-
tone deacetylase 1/2 (HDAC1/2) during infection (19, 20). In
addition, ICP0 has been shown to function as an E3 ubiquitin
ligase (5, 46). This activity directs a number of cellular pro-
teins, including components of nuclear ND10 domains and
centromeres for proteasomal degradation (4, 14, 15, 30). ICP0
also binds a cellular ubiquitin-specific protease, USP7, which
contributes to the activities of ICP0 in infection by preventing
its degradation (3, 17). Consistent with its role in the disrup-
tion of nuclear complexes and its role in gene expression, ICP0
localizes to the nucleus early in infection (1, 16). However,
during the course of infection it relocalizes to the cytoplasm,
where it is located in discrete domains (28, 31). Moreover, in
some cell lines, such as primary human fibroblasts, ICP0 is
predominantly cytoplasmic throughout infection (28). Once in
the cytoplasm, ICP0 is believed to associate dynamically with
proteasomes and has been shown to induce the accumulation
of colocalizing conjugated ubiquitin, suggesting that its E3
ubiquitin ligase activity is functional in the cytoplasm as well as
the nucleus (13). A recent study has shown that another IE
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protein, ICP27, is required for the translocation of ICP0 from
the nucleus to the cytoplasm (43). Interestingly, these authors
showed that in cells infected with HSV-1 expressing an ICP27
mutant that was unable to relocalize ICP0 to the cytoplasm,
ICP0 was not assembled into the virion (43). Hence, the cyto-
plasmic localization of ICP0 would seem to be fundamental for
its packaging. Nonetheless, cytoplasmic localization of ICP0 is
not sufficient for its assembly into the virion, as our own pre-
vious data have shown that VP22 is also required for ICP0
packaging, even though ICP0 localizes efficiently to the cyto-
plasm in the absence of VP22 (9). In this case, we have pro-
posed that VP22 recruits ICP0 from the cytosol, once it has
translocated from the nucleus, to ICP0-specific domains in the
cytoplasm. We have postulated that these cytoplasmic domains
represent a step on the virus assembly pathway (9, 40).
In this current study we set out to determine the mechanism
by which VP22 is involved in the recruitment of ICP0 into the
virus structure. We show that ICP0 and VP22 are present in a
complex in infected cells and that VP22-ICP0 complex forma-
tion requires the N terminus of VP22. We also show that ICP0
is assembled into a region of the tegument that is tightly asso-
ciated with the capsid and that its assembly into the virus
correlates with its ability to complex with VP22. Localization of
ICP0 to our previously characterized cytoplasmic domains is
not, however, sufficient for ICP0 assembly. Interestingly, the
RING finger of ICP0 is required for complex formation and
assembly into the virion, but it is not yet clear if this is a
physical or functional requirement. While VP22 is not required
for ICP0 translocation to the cytoplasm per se, the expression
of the N terminus alone inhibits translocation, resulting in
nuclear retention of ICP0. We conclude that the HSV-1 teg-
ument protein VP22 is an important molecular partner of the
IE protein ICP0 that recruits it to the virion but may also
influence its activities in other ways.
MATERIALS AND METHODS
Cells and viruses. Vero, U2OS, and BHK cells were grown in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% newborn calf serum
and antibiotics. Viruses were routinely grown in BHK or Vero cells and titrated
on Vero cells. The parental virus strain used in this study was strain 17 (s17) of
HSV-1. Strains sc16 and HFEM were kindly provided by Helena Browne (De-
partment of Pathology, University of Cambridge) and Peter O’Hare (Marie
Curie Research Institute, Surrey, United Kingdom), respectively. The recombi-
nant virus expressing green fluorescent protein (GFP)-tagged VP22 (166v) and
the VP22 deletion mutant (169v) that expresses GFP in place of VP22 have been
described previously (9, 11). Viruses expressing residues 108 to 301, 160 to 301,
1 to 212, and 1 to 165 as GFP fusion proteins have also been described before
(22). Virus mutants in ICP0 FXE, E52X, M1, D12, and dl1403 (12, 34) or
expressing yellow fluorescent protein (YFP)-tagged ICP0 (18) were kindly pro-
vided by Roger Everett (MRC Virology Unit, University of Glasgow).
Virion and capsid purification. Extracellular virions were purified on Ficoll
gradients from the infected cell medium of 5  108 BHK cells, as described
previously (11). Intranuclear capsid preparations were carried out from nuclear
extracts made from 5  108 BHK cells infected at a multiplicity of infection of
0.05. After 3 days, cell pellets were solubilized in phosphate-buffered saline
(PBS)/1% NP-40 containing protease inhibitors, and nuclei were pelleted at low
speed following a 30-min incubation on ice. Nuclei were washed in PBS, then
resuspended in PBS, and subjected to 3 rounds of freeze-thawing. Cell debris was
removed by centrifugation, and the supernatant was purified by centrifugation
for 1 h at 25,000  g through a 30% sucrose cushion in an SW41 rotor. The
resulting pellet was resuspended in 1 ml PBS and fractionated by centrifugation
for 1 h at 25,000  g through a 15 to 50% sucrose gradient. Fractions were
collected across the gradient and precipitated in 10% trichloroacetic acid (TCA).
Virion stripping experiments. Equivalent amounts of virions were pelleted at
2,300  g for 5 min at 4°C and resuspended in 50 l of 10 mM Tris-HCl (pH 7.5),
1 mM EDTA, 1% NP-40, and NaCl ranging from 0.1 to 1 M. The virions were
then incubated for 15 min at room temperature and pelleted again to separate
soluble from insoluble proteins.
Antibodies. Monoclonal antibodies to GFP and HSV-1 major capsid protein
VP5 were obtained from Clontech and Autogen Bioclear, respectively. The
monoclonal anti-VP16 (LP1) and anti-gD (LP14) antibodies were kindly pro-
vided by Helena Browne (Department of Pathology, University of Cambridge).
The anti-VP22 polyclonal antibodies AGV031 (N-terminal specific) and AV600
(C-terminal specific) have been described previously (10). Monoclonal anti-ICP0
(monoclonal antibody 11060) and anti-ICP27 antibodies were kindly provided by
Roger Everett (MRC Virology Unit, University of Glasgow) and Steve Rice
(University of Minnesota), respectively. Anti-PML polyclonal antibody DB75
was provided by Peter O’Hare (MCRI, Surrey, United Kingdom). The anti-
conjugated ubiquitin antibody FK2 was obtained from Enzo Life Sciences.
Immunoprecipitation assay. Vero cells grown in 6-cm dishes were infected
with the relevant viruses at a multiplicity of infection of 1. After 20 to 24 h, the
cells were washed twice with PBS, solubilized in 1 ml RIPA buffer (50 mM Tris,
pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Na deoxycholate, 1% NP-40) and incu-
bated on ice for 20 min. The cells were then centrifuged at 12,000  g for 30 min
at 4°C, and the supernatant was collected. The appropriate antibody was added
to between 400 and 800 l of lysate and incubated for 3 h at 4°C with rotation.
Forty microliters of protein A Sepharose beads were added and incubated
overnight at 4°C with rotation, and the resulting protein A-antibody complexes
were washed five times with PBS. The immunoprecipitated proteins were then
analyzed by SDS-PAGE followed by Western blotting.
SDS-polyacrylamide gel electrophoresis and Western blotting. Protein sam-
ples were analyzed on 10% polyacrylamide gels and electrophoresed in SDS-
Tris-glycine buffer. Following electrophoresis, gels were either stained with Coo-
massie blue (Thermo Scientific), silver stained (Perbio), or transferred to
nitrocellulose for analysis by Western blotting. Western blots were developed
using enhanced chemiluminescence (Pierce).
Immunofluorescence. Cells for immunofluorescence were grown on 16-mm
coverslips in individual wells of a six-well plate. Cells were fixed for 20 min in 4%
paraformaldehyde, permeabilized for 10 min in PBS containing 0.5% Triton
X-100, and blocked by incubation for 10 min in PBS containing 10% newborn
calf serum. Primary antibody was added for 15 min in the same solution, and
after the cells were washed extensively in PBS, the appropriate secondary anti-
body (all from Vector Labs) was added in a block solution and incubated for a
further 10 min. The coverslips were then washed extensively in PBS and mounted
in Vectashield or Mowiol containing 4,6-diamidino-2-phenylindole (DAPI)
(Vector Labs). Images were acquired using a Zeiss LSM510 Meta confocal
microscope. Resulting images were processed using Adobe Photoshop software.
RESULTS
ICP0 is packaged into the tegument of the HSV-1 virion.
Our previous results have indicated that ICP0 is present in
gradient-isolated preparations of extracellular HSV-1 virions
that have been purified from the supernatant of infected
BHK21 cells. To confirm that ICP0 is a true virion component
and not simply a contaminant of our virion preparations, we
first analyzed the concentration of ICP0 across a Ficoll gradi-
ent used to isolate virions. A crude preparation of extracellular
s17 virions was produced by pelleting virus at high speed from
infected cell supernatant. The resulting pellet was resuspended
in PBS and centrifuged through a 5 to 15% Ficoll gradient. Ten
fractions were collected across the gradient, and the content of
each was analyzed by titration on Vero cells for the presence of
infectious virus, showing that the peak of infectivity was
present in fraction 7 (Fig. 1A). Samples of the fractions were
also analyzed by SDS-PAGE and Western blotting for the
major capsid protein VP5 and ICP0. These blots revealed that
both ICP0 and VP5 also peaked in fraction 7, confirming that
ICP0 copurifies with capsids and infectivity.
We next wished to determine in which compartment of the
virus ICP0 is packaged. To this end, we used detergent treat-
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ment to fractionate extracellular virions into envelope and
tegument/capsid fractions. Equal aliquots of virions were ex-
tracted in buffer containing salt concentrations ranging from
0.2 to 1 M NaCl to discriminate between loosely and tightly
associated tegument proteins. The resulting fractions were an-
alyzed by SDS-PAGE and then by Coomassie blue staining or
Western blotting with antibodies specific for the capsid protein
VP5, the envelope protein gD, and the tegument proteins
VP16 and VP22. As would be expected, the envelope glyco-
protein gD was completely removed from the virions at the
lowest concentration of NaCl (Fig. 1B, gD). In contrast, the
capsid protein VP5 remained in the pellet fraction even in
NaCl concentrations as high as 1 M (Fig. 1B, VP5). Both
tegument proteins VP16 and VP22 can be seen dividing into
two populations; one is removed with 0.4 M NaCl, but the
second one remains tightly associated with the capsid in the
pellet (Fig. 1B, VP16 and VP22). Interestingly, ICP0 behaves
like the capsid protein and remains entirely in the pellet frac-
tion of the virions, even at 1 M NaCl (Fig. 1B, ICP0). These
results suggest that ICP0 is tightly associated with the capsid
within the virus structure.
HSV-1 capsids are assembled in the nucleus of the cell.
Therefore, we wished to determine if ICP0 was present on
intranuclear capsids. Nuclear extracts from Wt virus-infected
BHK21 cells were subjected to centrifugation on a sucrose
gradient, and fractions were collected across the gradient and
analyzed by SDS-PAGE and then by silver staining. The capsid
population was seen to peak in fraction 8 of the gradient (Fig.
1C), which was then analyzed by Western blotting beside an
equivalent concentration of purified extracellular virions,
based on VP5 content (Fig. 1D, VP5). Blotting for the tegu-
ment protein VP16, which has been shown to be present on
primary virions in the perinuclear space (35) and which is
present in the nucleus at high concentrations, revealed that
these intranuclear capsids contained no VP16 and could there-
fore be considered highly purified. Furthermore, blotting for
ICP0 showed that ICP0 was also absent from the intranuclear
capsids, suggesting that ICP0 is not added to capsids within the
FIG. 1. ICP0 is an HSV-1 tegument protein. (A) Extracellular s17 virions were centrifuged through a 5 to 15% Ficoll gradient, and fractions
were taken across the gradient. Each sample was analyzed for infectivity (top) or subjected to Western blotting for the major capsid protein VP5
or ICP0. (B) Purified extracellular s17 virions were fractionated using detergent and increasing concentrations of NaCl. Soluble (s/n) and insoluble
(pellet) fractions were separated by pelleting and then analyzed by SDS-PAGE followed by Coomassie blue staining (top panel) or Western
blotting for a range of virus structural proteins. The sizes of the molecular weight markers (in thousands) are indicated on the left. (C) Intranuclear
capsids from s17-infected cells were centrifuged through a 15 to 50% sucrose gradient, and fractions were collected across the gradient. Each
sample was analyzed by SDS-PAGE followed by silver staining. (D) Equivalent amounts of intact s17 virions and s17 capsids from fraction 8, based
on their VP5 content, were analyzed by Western blotting for VP5, VP16, and ICP0.
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nucleus but at a later stage downstream in the virus assembly
pathway.
ICP0 coimmunoprecipitates with VP22 throughout infec-
tion. Previously, we have shown that ICP0 requires the pres-
ence of VP22 to be assembled into the HSV-1 virion (9).
Hence, we wished to determine if this requirement reflected
the presence of a VP22-ICP0 complex within the infected cell.
Vero cells were infected with HSV-1 (s17) expressing GFP-
tagged VP22 at a multiplicity of infection of 1, and lysates
harvested in RIPA buffer at various times throughout infec-
tion. VP22 was then immunoprecipitated with an anti-VP22
antibody, and resulting immunocomplexes were analyzed by
SDS-PAGE and Western blotting. As a control for nonspecific
binding of ICP0 to the VP22 antibody, the same experiment
was also carried out with cells infected with our 22 mutant
virus expressing GFP in place of VP22. Western blotting of the
input samples with a GFP antibody showed that the GFP-22
and 22 mutant infections progressed with similar efficiencies
through the time courses (Fig. 2A, Inputs, GFP). As we have
noted before, ICP0 levels for the 22 mutant infection were
consistently lower than those for the GFP-22 infection (Fig.
2A, Inputs, ICP0). Blotting of the resulting complexes with a
GFP antibody indicated that VP22 was successfully immuno-
precipitated from 12 h onward (Fig. 2A, IPs, GFP). Interest-
ingly, blotting of these complexes for ICP0 showed that ICP0
was efficiently coimmunoprecipitated with VP22 at these times
of infection (Fig. 2A, IPs, ICP0). No ICP0 was detected in the
immunoprecipitation samples from the 22 mutant-infected
cells, confirming that pulldown of ICP0 with the VP22 anti-
body was specific to the presence of GFP-VP22 in the extract.
FIG. 2. VP22 and ICP0 form a complex in infected cells. (A) Vero cells infected with s17 expressing GFP in place of VP22 (s1722) or
expressing GFP-tagged VP22 (s17-GFP-22) at a multiplicity of infection of 1 were harvested at times ranging between 6 and 24 h after infection,
and immunoprecipitations carried out with a VP22 polyclonal antibody. The original input samples and resulting complexes were analyzed by
Western blotting for GFP or ICP0. The sizes of the molecular weight markers (in thousands) are indicated on the left. (B) As described in the
legend for panel A, but using s17 and s17-GFP-22 viruses. (C) Vero cells infected with the same viruses as those shown in panel A were harvested
20 h after infection and immunoprecipitated with a polyclonal anti-GFP antibody. The resulting complexes were analyzed by Western blotting for
GFP and ICP27. (D) Vero cells infected with either s17 expressing YFP-tagged ICP0 or the ICP0 deletion virus dl1403 (ICP0) were treated as
described in the legend for panel C and analyzed by Western blotting for ICP0 and ICP27. Asterisk denotes polyclonal heavy chain.
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To confirm that the VP22-ICP0 pulldown occurred in wild-
type virus-infected cells and was not specific to the expression
of GFP-tagged VP22, a similar experiment was carried out
comparing time courses of Vero cells infected with HSV-1–
GFP-22 or HSV-1 s17. Western blotting of input samples again
showed that both infections had progressed at similar rates and
that in this case, ICP0 was efficiently expressed in s17 and
GFP-22 infections (Fig. 2B, Inputs). Immunoprecipitation of
VP22 also resulted in the pulldown of ICP0 in both infections,
confirming that VP22 and ICP0 are present in an infected cell
complex (Fig. 2B, IPs).
ICP27 is not present in the ICP0-VP22 complex. It has
recently been published that, like VP22, ICP27 is required for
the virion incorporation of ICP0 (43), and therefore, we hy-
pothesized that ICP27 may be present in the same infected cell
complex as VP22 and ICP0. Hence, an extract of cells infected
with the GFP22-expressing virus was immunoprecipitated with
an anti-GFP antibody to pull down VP22-containing com-
plexes, and the resulting complexes were tested for the pres-
ence of ICP27. At the same time, an extract from 22 mutant-
infected cells expressing GFP in place of VP22 was used as a
control for potential nonspecific binding of ICP27 to the anti-
body. As shown in Fig. 2C, although ICP27 expression was
readily detectable in the infected cell extracts, it was not
present in the GFP-22 pulldown complex (Fig. 2C, IP). As
ICP27 has a more defined relationship with ICP0, we also
immunoprecipitated ICP0 and tested for the presence of
ICP27 in the resulting complexes. In this case, Vero cells were
infected with s17 expressing YFP-tagged ICP0 or s17 lacking
ICP0 and immunoprecipitated with an anti-GFP antibody (Fig.
2D). Once again, although ICP0 was efficiently precipitated
and ICP27 was present in the input extract, no ICP27 was
pulled down with ICP0 (Fig. 2D, IPs). Taken together, these
results suggest that ICP27 does not form a complex with ICP0
or VP22 in the infected cell, in spite of being required for
efficient ICP0 recruitment into the tegument.
It has been published by others that ICP27 is not associated
with virions of HSV-1 (43, 52), a result that would correlate
with our inability to detect ICP27 in the VP22-ICP0 complexes
in infected cells. To confirm that ICP27 was absent from viri-
ons, we fractionated extracellular virions across a Ficoll gradi-
ent, in this case from the HFEM strain of HSV-1, as described
in the legend for Fig. 1A, and analyzed the resulting samples
for infectivity and the presence of the capsid protein VP5 and
ICP27 by Western blotting (Fig. 3A). Surprisingly, we were
able to detect ICP27 in the peak infectious sample, in which it
copurified with the capsid protein (Fig. 3A, fraction 7). These
results were somewhat unexpected, and therefore, we next
looked for ICP27 in extracellular virions from two other strains
of HSV-1, s17 and sc16, and were able to readily detect the
protein in these particles too, confirming that ICP27 is a com-
ponent of virions (Fig. 3B, s17 and sc16). Furthermore, deter-
gent stripping of virions revealed that ICP27 was present in the
tegument/capsid fraction of the virions (Fig. 3C).
Because it has been shown that ICP27 is required for ICP0
assembly into the virion, these results raised the possibility that
although we could not detect ICP27 in the ICP0-VP22 com-
plex, ICP0 and ICP27 may enter the virion structure by the
same VP22-specific mechanism. Therefore, we tested 22 mu-
tant virions for the presence of ICP27 but found that ICP27
packaging was unaltered in the absence of VP22 and ICP0
packaging (Fig. 3B, 22). Taken together, these results suggest
that ICP27 is recruited into the virion by an ICP0- and VP22-
independent mechanism.
Virion recruitment of ICP0 requires the N terminus of
VP22. To further investigate the role of VP22 in the recruit-
FIG. 3. ICP27 is packaged into the HSV-1 tegument in a VP22-independent mechanism. (A) Extracellular HFEM virions were centrifuged
through a 5 to 15% Ficoll gradient, and fractions taken across the gradient. Each sample was analyzed for infectivity (top) or subjected to Western
blotting for the major capsid protein VP5 or ICP27. (B) Approximately equivalent amounts of s17, s1722, and sc16 virions were analyzed by
Western blotting for VP5, VP22, ICP0 and ICP27. The sizes of the molecular weight markers (in thousands) are indicated on the left. (C) Strain
HFEM virions were fractionated into envelope (Env) and tegument-capsid (Te/C) fractions using detergent and 0.1 M NaCl. Soluble and insoluble
fractions were separated by pelleting and then analyzed by Western blotting for the capsid protein VP5, the tegument protein VP16, the envelope
protein gD, and ICP27.
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ment of ICP0 into the virion, we used viruses expressing trun-
cation mutants of VP22 fused to GFP (Fig. 4A) that have been
characterized previously (22). Extracellular virions were puri-
fied from the viruses shown in Fig. 4A, together with the 22
mutant virus, and analyzed by Western blotting for the pres-
ence of ICP0. As previously shown, assembly of VP22 did not
require the N-terminal half of the protein (Fig. 4B, VP22,
compare 1 to 301 with 160 to 301) but did require the C-
terminal region (Fig. 4B, VP22, compare 1 to 301 with 1 to
212). Also, as we have shown before, assembly of ICP0 was
seen to be dependent on VP22, as the 22 mutant virions
contained no detectable amounts of ICP0 (Fig. 4B, ICP0, com-
FIG. 4. The N terminus of VP22 is required for ICP0 assembly into the virion. (A) Line drawing of the VP22 truncation mutants used in this
study. (B) Equivalent amounts of virions from the viruses described in the legend for panel A were analyzed by Western blotting for VP22, VP5,
and ICP0. (C) Immunoprecipitations using a polyclonal GFP antibody were carried out on Vero cells infected with HSV-1 expressing full-length
GFP-22 (1 to 301), the two N-terminal VP22 truncation mutants (108 to 301 and 160 to 301), or GFP in place of VP22 (22), 20 h after infection
at a multiplicity of infection of 1. The resulting complexes were analyzed by Western blotting for the C terminus of VP22 or ICP0. The sizes of
the molecular weight markers (in thousands) are indicated on the left. (D and E) As described in the legend for panel C, using cells infected with
HSV-1 expressing full-length VP22 (1 to 301), the N-terminal half of VP22 (1 to 165), or GFP in place of VP22 (22). Western blots were carried
out using antibodies for the N terminus of VP22 or ICP0. (F) As described in the legend for panel D, using cells infected with HSV-1 expressing
GFP in place of VP22 (22) or the C-terminal truncation (1 to 212).
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pare 1 to 301 with 22). Interestingly, the level of ICP0 present
in virions that packaged residues 108 to 301 of VP22 was
greatly reduced and was undetectable in virions that packaged
residues 160 to 301 of VP22, in spite of the assembly of the
VP22 variants being unaffected (Fig. 4B, ICP0). ICP0 was also
absent from virions made from cells expressing the 1-to-212
and 1-to-165 variants of VP22, which themselves are not pack-
aged (Fig. 4B, ICP0).
We next addressed the ability of these VP22 truncation
mutants to form a complex with ICP0. First, the N-terminal
truncation viruses were used in coimmunoprecipitation assays
on extracts made at 20 hours postinfection (h.p.i), in which
VP22 was immunoprecipitated using an antibody specific for
the C terminus of VP22, and the resulting complexes blotted
for ICP0. In this case, while full-length and N-terminally trun-
cated VP22 viruses were precipitated in equivalent amounts
(Fig. 4C, IP, VP22), the content of ICP0 present in the immu-
nocomplexes was quite different, with deletion of the N-termi-
nal third of the protein greatly reducing the pulldown of ICP0
and deletion of the N-terminal half of VP22 abolishing the
pulldown of ICP0 (Fig. 4C, IP, ICP0). These results correlate
directly with the level of ICP0 assembly into the respective
virions (Fig. 4B), confirming that VP22 has a major role in the
assembly pathway of ICP0.
To assess if the N-terminal half of VP22 was sufficient for
complex formation with ICP0, the mutant virus expressing only
residues 1 to 165 of VP22 was used in a coimmunoprecipitation
assay, in this case using an antibody specific to the N terminus
of VP22. Western blotting of the resulting pulldown complexes
revealed that ICP0 was not present in the complex bound to
the VP22 antibody, a result that was highly reproducible (Fig.
4D and E). This implies that this region of VP22 may be
necessary but is not sufficient for complex formation with ICP0.
In contrast, a similar pulldown carried out on cells expressing
residues 1 to 212 of VP22 resulted in the efficient coprecipita-
tion of ICP0, indicating that this region of the protein is suf-
ficient to form a complex with ICP0 (Fig. 4F). Although this
mutant expresses a low level of the VP22 1-to-212 mutant
protein (Fig. 4F, input), as we have shown before (22), the
amount of VP22 present in the immunoprecipitation complex
was comparable to those of the other samples (Fig. 4F, IP). As
this region of VP22 is not itself assembled into the virion (Fig.
4B), the fact that ICP0 is not assembled, even though ICP0 can
complex with VP22, is consistent with a physical requirement
for VP22 in the assembly of ICP0 (Fig. 4B).
ICP0 localization in VP22 mutant virus infections. We have
previously shown that, following translocation of ICP0 from
the nucleus to the cytoplasm of HSV-1-infected cells, VP22
and ICP0 colocalize in discrete cytoplasmic domains (9). Fur-
thermore, while ICP0 was able to translocate to the cytoplasm
of cells infected with our 22 mutant virus, its localization to
these cytoplasmic domains was shown to be greatly reduced, a
result that led us to postulate that these cytoplasmic domains
were on the virus assembly pathway for HSV-1 (9). As the
colocalization of VP22 and ICP0 may be representative of their
presence in the same complex as well as their recruitment into
the virus tegument, we wished to determine if expression of
any of the VP22 truncation mutants affected the cytoplasmic
localization of ICP0. Vero cells were infected with HSV-1
expressing GFP-tagged full-length or truncated VP22 or GFP
in place of VP22 (22 mutant) at a multiplicity of infection of
10. Six hours after infection, cells were fixed and analyzed by
immunofluorescence with anti-ICP0. As described before,
ICP0 colocalized with a subset of GFP-positive cytoplasmic
domains containing full-length VP22 (Fig. 5, 1 to 301), while in
the absence of VP22, ICP0 was predominantly in a diffuse
cytoplasmic localization (Fig. 5, 22). In cells infected with
HSV-1 expressing the N-terminal 212 residues of VP22, which
we have shown above to complex with ICP0, ICP0 was also
present in cytoplasmic domains (Fig. 5, 1 to 212). However, in
this case, VP22 was predominantly nuclear and in spite of their
ability to coimmunoprecipitate, there was little evidence of
colocalization at the cytoplasmic domains or elsewhere in the
cell. Likewise, in cells infected with HSV-1 expressing the
C-terminal half of VP22, which we have shown above does not
complex with ICP0 but is packaged into the virus, ICP0 local-
ized efficiently to its cytoplasmic domains. Hence, interaction
with VP22 is not required for ICP0 to localize to these do-
mains. Furthermore, a presence in these domains is not suffi-
cient for ICP0 assembly into the virus. Strikingly, in cells in-
fected with HSV-1 expressing the N-terminal half of VP22,
shown above to be necessary but not sufficient for complex
formation with ICP0, ICP0 localization is retained in its nu-
clear punctate pattern (Fig. 5, 1 to 160). Even at later time
points up to 16 h after infection, there is little evidence that
ICP0 can translocate to the cytoplasm in cells infected with this
virus (data not shown). We would suggest then that this region
of VP22 functions as a dominant negative inhibitor of ICP0
translocation to the cytoplasm.
ICP0 is biologically active in cells infected with VP22 trun-
cation mutants. A major characterized role of ICP0 during
infection is the localization to ND10 domains and subsequent
degradation of PML and other components localized in those
domains. We wanted to ensure that ICP0 was functioning
correctly in our VP22 truncation mutant viruses, and therefore,
Vero cells infected with each of the viruses, as described in the
legend for Fig. 5, were fixed at 6 h after infection and stained
for immunofluorescence using a polyclonal anti-PML anti-
body. Uninfected cells showed the characteristic pattern for
PML staining in punctate nuclear domains (Fig. 6, mock). In
contrast, infection with wild-type virus had efficiently dispersed
PML at the time of fixation, and no ND10 domains in the
infected cell nuclei were obvious (Fig. 6, 1 to 301). Likewise, all
mutant virus infections, including the 22 mutant infection,
caused the dispersal of PML from ND10 domains (Fig. 6),
confirming that ICP0 was functional in all these infections.
Interestingly, in cells infected with virus expressing only the
N-terminal half of VP22, which we have shown above to result
in the retention of ICP0 in nuclear domains, PML behavior
was identical to that in the other infections, suggesting that the
retention of ICP0 in nuclear domains is not a consequence of
inefficient PML degradation (Fig. 6, 1 to 212).
Another measure of ICP0 activity is its ability to induce the
accumulation of colocalizing conjugated ubiquitin in the in-
fected cell (13). Hence, we next measured this activity by car-
rying out the same infections described in the legend for Fig. 6
and then staining for immunofluorescence with the anti-ubiq-
uitin antibody FK2 that detects both poly- and monoubiquitin-
ated species. In uninfected cells, ubiquitin was predominantly
nuclear in a speckled and diffuse pattern (Fig. 7, mock). In
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contrast, in cells infected with Wt virus expressing GFP-22,
FK2 staining was present in cytoplasmic punctate domains that
colocalized with a subset of GFP-positive domains (Fig. 7, 1 to
301), in a pattern similar to that seen for ICP0 in wild-type
infection (Fig. 5, 1 to 301). Indeed, in all mutant virus infec-
tions, FK2 staining reflected the respective ICP0 staining
(compare Fig. 7 and 5). Of note is the fact that in cells infected
with the virus expressing the N-terminal half of VP22, which
retains ICP0 in nuclear domains, ubiquitin accumulates to high
levels in nuclear domains, thereby again reflecting the relative
FIG. 5. ICP0 localizes to cytoplasmic domains in the absence of interacting VP22. Vero cells on coverslips were infected with the GFP-
expressing viruses described in the legend for Fig. 4A at a multiplicity of infection of 10 and fixed with 4% paraformaldehyde 6 h later.
Immunofluorescence was carried out for ICP0 (red).
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ICP0 localization (Fig. 7, 1 to 212). Taken together with the
PML degradation results, these results imply that ICP0 is func-
tional in all our VP22 mutant viruses, and therefore, the lack of
assembly is not due to the presence of inactive ICP0.
The RING finger of ICP0 is necessary but not sufficient for
recruitment into the virion. To investigate the domains of
ICP0 required for interaction with VP22, we carried out co-
immunoprecipitations from cells infected with a number of
FIG. 6. PML is dispersed from ND10s in all VP22 mutant virus infections. Vero cells on coverslips were either uninfected (mock) or infected
with the GFP-expressing viruses described in the legend for Fig. 4A at a multiplicity of infection of 10 and fixed with 4% paraformaldehyde 6 h
later. Immunofluorescence was carried out for PML, and nuclei were stained with DAPI.
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ICP0 mutant viruses kindly provided to us by Roger Everett,
Glasgow (Fig. 8A). In this case, infections were carried out at
a multiplicity of infection of 1 in U2OS cells, as ICP0 muta-
tions are known to have little effect on virus growth in this cell
line (53), and harvested 20 h later. Resulting immunocom-
plexes were analyzed by Western blotting for VP22 and ICP0,
with a 22 mutant-infected cell lysate being used as a negative
control. VP22 was expressed and precipitated in equivalent
FIG. 7. ICP0 induces colocalizing, conjugated ubiquitin in all VP22 mutant virus infections. Vero cells on coverslips were either uninfected
(mock) or infected with the GFP-expressing viruses described in the legend for Fig. 4A at a multiplicity of infection of 10 and fixed with 4%
paraformaldehyde 6 h later. Immunofluorescence was carried out for conjugated ubiquitin using antibody FK2 (red).
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amounts in all infections, indicating that mutation of ICP0 has
no effect on VP22 expression levels at least in U2OS cells (Fig.
8B, VP22). Levels of ICP0 were more variable in the infected
cell lysates, with the 22 and FXE ( RING finger) mutant
viruses consistently expressing less ICP0 than the other viruses
(Fig. 8B, ICP0, input). Nonetheless, the coimmunoprecipita-
tions indicated that ICP0 lacking its RING finger did not form
a complex with VP22 during infection (Fig. 8B, ICP0, IP).
Longer exposures of this blot showed no evidence of an ICP0
 RING finger mutant pulldown with VP22 (data not shown).
In contrast, ICP0 lacking its C terminus (E52X) or mutated in
its USP7 binding domain within the C terminus (D12 and M1)
precipitated efficiently with VP22 (Fig. 8B, ICP0, IP). These
results suggest that the RING finger but not the C terminus of
ICP0 is required for complex formation with VP22.
We next wished to correlate the ability of these ICP0 mu-
tants to form VP22 complexes with their relative assemblies
into virions. Western blotting was carried out on extracellular
virions from the mutant viruses shown in Fig. 8A, together with
the ICP0 mutant virus dl1403, and ICP0 and VP22 levels
were compared to that present in Wt (s17) virions. Blotting for
the capsid protein VP5 confirmed that all virions had been
loaded in equivalent amounts (Fig. 8C, VP5), while blotting for
VP22 in the ICP0 mutant virus indicated that VP22 packag-
ing was not dependent on ICP0 (Fig. 8C, VP22, dl1403). ICP0
lacking its RING finger was not detected in virions, consistent
with our failure to pull down this variant of ICP0 with VP22
(Fig. 8C, FXE). However, ICP0 lacking its C terminus was also
not packaged into virions, in spite of its ability to interact
efficiently with VP22 (Fig. 8C, E52X). In contrast, the ICP0
variants that were mutated specifically in their USP7 binding
domains were packaged at levels higher than Wt levels (Fig.
8C, D12 and M1). Blotting virions for VP22 showed that this
increase in ICP0 content was not a result of increased VP22
levels in the virion (Fig. 8C, VP22, D12, and M1). Likewise, the
lack of packaging of the ICP0 RING finger and C-terminal
FIG. 8. Virion assembly of ICP0 requires its RING finger and its C terminus. (A) Line drawing of the ICP0 mutants used in this study.
(B) U2OS cells were infected with all the viruses shown in panel A together with the 22 mutant virus at a multiplicity of infection of 1 and
harvested 20 h later. Immunoprecipitations were carried out using a VP22 antibody, and the resulting complexes were analyzed by Western blotting
for VP22 and ICP0. (C) Equivalent amounts of extracellular virions from the viruses shown in panel A, together with the ICP0 deletion mutant
(dl1403), were analyzed by Western blotting for VP5, VP16, VP22, and ICP0. (D) Extracellular virions from the USP7 binding site mutant D12
were centrifuged through a 5 to 15% Ficoll gradient, and fractions were taken across the gradient. Each sample was analyzed for infectivity (top)
or subjected to Western blotting for the major capsid protein VP5 or ICP0.
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mutants was also not a reflection of reduced VP22 levels in
these virions (Fig. 8C, VP22, FXE, and E52X).
To confirm that the increased ICP0 level present in virions
made from D12-infected cells was real, a crude preparation of
virions was fractionated on a 5 to 15% Ficoll gradient, and 1-ml
fractions were collected. Each fraction was then analyzed by
titration for the presence of infectivity and by Western blotting
for the presence of ICP0. The ICP0 content across the gradient
was seen to cofractionate with both the major capsid protein
VP5 and infectivity (Fig. 8D). Hence, these virions truly pack-
age increased levels of ICP0, albeit a variant of ICP0 mutated
in its USP7 binding domain.
DISCUSSION
The HSV-1 IE protein ICP0 is expressed early in infection
and is involved in establishing the correct environmental con-
ditions within the cell to allow optimal lytic virus replication.
As such, it counteracts several antiviral pathways that the cell
may use to inhibit virus replication, including genome silencing
and the interferon response. With such activities in its reper-
toire, the packaging of ICP0 into the virus structure, so that it
is delivered to the cell immediately upon virus entry, would be
a logical mechanism for the virus to utilize. However, although
it has been some years since ICP0 was originally proposed to
be a virion component (52), it is only recently that the concept
has been explored in more detail. Here we provide further
compelling evidence for the presence of ICP0 in the virus and,
together with a number of other recent publications, prove that
the presence of ICP0 in extracellular virion preparations is not
due to sample contamination but is the result of specific as-
sembly of the protein into the tegument compartment of the
virus structure (7, 9, 32). In this paper we have also shown for
the first time that the IE protein ICP27 is additionally pack-
aged into the tegument of the virus. As ICP4 has also been
shown to be present in the HSV-1 virion (9, 43, 51), a unifying
theme of assembly of apparent nonstructural regulatory pro-
teins seems to be emerging.
VP22-specific assembly of ICP0. In our previous studies we
have shown that virions made from HSV-1 lacking the tegu-
ment protein VP22 fail to package ICP0, suggesting an impor-
tant relationship between these two proteins (9). Nonetheless,
in this situation the complete deletion of the VP22 open read-
ing frame from the HSV-1 genome may have had an indirect
effect on the packaging of ICP0. Indeed, the fact that intracel-
lular ICP0 levels are reduced in the absence of VP22 has led
others to suggest that it may be the relative level of ICP0 that
dictates its assembly into the virion rather than a specific in-
teraction and/or localization (8). Importantly, however, we
now show that VP22 and ICP0 are present in a complex within
the infected cell that is dependent on the N terminus of VP22.
Moreover, the ability of ICP0 to complex with VP22, in both
VP22 and ICP0 mutant viruses, directly reflects its level of
recruitment into the virion with VP22 (Table 1), implying that
this interaction is the main determinant of ICP0 assembly.
Taking these results together with our previous work, we con-
clude that, in our hands at least, an immunoprecipitated VP22-
specific complex from infected cells contains gE, gM, VP16,
and ICP0 but not gD or VP13/14 (45). We and others have
previously identified binding domains for VP16 and gE within
the C-terminal half of VP22 (22, 36, 37, 45), whereas, as we
have shown here, the ICP0 interaction domain requires the
N-terminal half of VP22. However, this region is not sufficient
for complex formation with additional sequences extending
into the VP16/gE binding domains being required (summa-
rized in Table 1). Hence, it is possible that VP16 and/or gE is
essential in stabilizing the VP22-ICP0-containing complex.
When considering molecular interactions involved in her-
pesvirus tegument assembly, the tegument is often referred to
as having an inner and outer compartment. This designation is
based on the ease with which tegument proteins can be ex-
tracted from the capsid structure and is often used to invoke an
order of assembly of the tegument: inner proteins added first
and outer proteins added later. The biochemical data pre-
sented here indicate that ICP0 is tightly associated with the
capsid of the virion, to the extent that its extraction profile is
akin to a true capsid protein rather than a tegument protein.
Early work showed that there were around 150 copies of ICP0
in the virion (52), a number that would fit with a location
proximal to the capsid. Furthermore, while the manuscript was
in preparation, Delboy and coworkers published a similar re-
sult demonstrating that ICP0 is tightly associated with the
capsid (7). The two tegument proteins that we looked at, VP16
and the ICP0 partner VP22, both separated into two popula-
tions, one that was readily extracted at a lower salt concentra-
tion and one that remained tightly associated with capsids
under all conditions. Thus, we would propose that the second,
tightly associated population of VP22 would be the one in-
volved in recruiting ICP0 into the tegument. It is not yet clear
what the differences between these two tegument protein pop-
ulations are, but the differential extractability may be dictated
by the respective binding partners of the two, the presence of
different posttranslationally modified forms, and/or their cel-
lular location of addition. Importantly, ICP0, VP16, and VP22
were all absent from our intranuclear capsids, confirming that
recruitment of even the tightly associated populations of these
molecules occurs outside the nucleus.
Cellular location of ICP0 assembly into the tegument. Cur-
rent data suggest that a pathway of events must occur in in-
fection for ICP0 to assemble into the virus. When ICP0 is first
TABLE 1. Binding and assembly properties of VP22
truncation mutantsf
VP22
residues
gE
bindinga
VP16
co-IPb
ICP0
co-IPc
Virion
VP22d
Virion
ICP0e
1–301     
108–301   /  /
160–301     
194–301    / 
1–212     
1–165     
a Binding of VP22 truncation mutants to the cytoplasmic tail of gE as de-
scribed previously (45).
b Infected cell coimmunoprecipitation of VP16 with VP22 mutants as shown
previously (22).
c Infected cell coimmunoprecipitation of ICP0 with VP22 mutants as shown
here.
d Virion assembly of VP22 truncation mutants as described previously (22).
e Virion assembly of ICP0 in viruses expressing VP22 truncation mutants as
described here.
f gE and VP16 assembly is unaffected by the absence of VP22. co-IP, coim-
munoprecipitation.
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expressed, it localizes to the nucleus, where it is involved in the
proteasomal degradation of ND10 and centromere compo-
nents and the inhibition of genome silencing. Recent studies
from the Roizman laboratory suggest that both of these events
must be complete before ICP0 translocates into the cytoplasm
(21, 26). Translocation requires, among other things, a late
gene product(s), as inhibition of DNA synthesis results in nu-
clear retention of ICP0 (31). Translocation also requires the IE
protein ICP27, and failure of ICP0 to translocate in this ICP27-
dependent manner abrogates its assembly into the virion (43).
Hence, cytoplasmic localization would seem to be a prerequi-
site for ICP0 assembly (43). Once in the cytoplasm, ICP0
requires VP22 for physical recruitment into the virion, but
where and how this recruitment takes place is not yet clear.
Like others, we have observed ICP0 in specific punctate do-
mains in the cytoplasm. In addition, in cells infected with virus
lacking the VP22 gene, ICP0 failed to localize to these puncta
to any degree (9). It is of note then that some full-length
GFP-VP22 is concentrated in these domains with ICP0 (Fig.
5), a result that led us to initially propose that VP22 brought
ICP0 to these sites where the proteins were then assembled
into the virus (9). However, several results from our fluores-
cence data have led us to modify this model. First, these studies
have clearly indicated that VP22 can be assembled into the
virus at Wt levels without exhibiting steady-state localization to
these cytoplasmic puncta, as indicated by the mutant protein
160 to 301. Second, ICP0 can localize efficiently to these sites
without interacting with VP22 and without being assembled,
again exemplified by the virus expressing mutant protein 160 to
301. Last, ICP0 and VP22 can form a complex without VP22
appearing at these sites, as is the case with VP22 mutant
protein 1 to 212. Hence, our data now suggest that the ICP0
puncta may be specific sites through which VP22 and other
tegument proteins transit prior to assembly but that final as-
sembly occurs at a different site. Variants of VP22 that are
assembled but do not interact with ICP0 may transit through
these ICP0 puncta but would not accumulate there because
ICP0 would not retain them, whereas variants that can interact
with ICP0 but are not assembled would not be targeted to
these sites in the first place. Therefore, VP22 localization to
the ICP0-specific puncta would be dictated by one of its other
binding partners rather than ICP0 itself. The failure of ICP0 to
accumulate in these puncta in the absence of VP22 may reflect
a more widespread phenotype of the 22 mutant virus, as
discussed below.
The role of the E3 ligase activity in ICP0 assembly. Our
studies of a number of ICP0 mutants implied that the RING
finger of the protein containing the E3 ligase activity was re-
quired for assembly into the virus, a result that has recently
been corroborated by Delboy and coworkers (7). We have
further shown that the ICP0 RING finger is necessary for
complex formation with VP22, suggesting that the RING fin-
ger may be the physical domain of ICP0 involved in the for-
mation of the VP22 complex. VP22 may therefore regulate the
activity of the ICP0 E3 ligase during infection. Nonetheless, we
have shown that all our VP22 mutants express functional ICP0,
with regard to PML degradation, and any role that VP22 may
play in ICP0 activity would presumably be subsequent to trans-
location to the cytoplasm. Alternatively, the ICP0 RING finger
mutant may simply be folded incorrectly for complex forma-
tion with VP22. In the case of the C-terminal truncation mu-
tant of ICP0 (E52X), this mutant forms a complex efficiently
with VP22 but is not recruited to the virion, in spite of Wt
levels of VP22 packaging. The C-terminal region of ICP0 ab-
sent from the E52X mutant incorporates USP7 binding, mul-
timerization, ND10 localization, and CoREST binding (Fig.
8A) (20, 33, 34), and any or a combination of these activities
may be required for ICP0 assembly into the virion. Given the
results presented here that ICP0 mutated specifically in the
USP7 binding domain is packaged to levels higher than Wt
ICP0 (ICP0 mutants D12 and M1), it is unlikely that USP7
binding is involved in recruiting ICP0 to the virion. This higher
level of ICP0 packaging in these mutants is counterintuitive, as
USP7 binding mutants of ICP0 have been shown to be less
stable in infected cells than in Wt ICP0 (3). Hence, the reason
for such enhanced packaging is yet to be determined but may
be related to the apparently enhanced levels of these mutants
seen by others in the cytoplasm of infected cells (13, 17).
Interestingly, the E52X mutant remains in the nucleus
throughout infection (34) and, like the previously described
ICP27 mutant which retains ICP0 in the nucleus (43), would be
predicted to be absent from the virion. The absence of both the
ND10 localization and the CoREST binding domains from
E52X means that this protein is unable to locate to and disrupt
ND10s or dissociate HDAC from the silencing complex (34).
Consistent with the model that both events are a prerequisite
for ICP0 translocation to the cytoplasm, the E52X protein is
retained in the nucleus.
A role for VP22 in the translocation of ICP0 from the nu-
cleus to the cytoplasm. The ICP0 translocation pathway would
suggest that VP22 does not have an involvement in the com-
partmentalization of ICP0. Furthermore, ICP0 translocates to
the cytoplasm normally in cells infected with our 22 mutant
virus (9). However, in this current study we have shown that
the N-terminal half of VP22, which in itself is unable to stably
complex with ICP0, retains ICP0 in the nucleus. Hence, the N
terminus alone seems to be functioning as a dominant-negative
inhibitor of ICP0 translocation. There are several situations
known in which Wt ICP0 is retained in the nucleus, such as
exposure to proteasomal inhibitors, failure to degrade PML
(21), treatment with HDAC inhibitors (27), inhibition of DNA
replication (31), or the presence of an ICP27 mutant (43). Our
immunofluorescence studies of PML in infected cells showed
clearly that ND10s were efficiently disrupted in this and all
VP22 mutant virus infections (Fig. 6), implying that the block
to ICP0 translocation occurs downstream of ND10 disruption.
Furthermore, DNA replication is not obviously affected in this
mutant, and although it is possible that the N terminus of VP22
inhibits the role of ICP27 in ICP0 translocation, our pulldown
experiments from infected cells revealed that ICP27 is not an
obvious binding partner of VP22. Unlike full-length VP22, the
dominant-negative N-terminal region of VP22 has a predom-
inantly nuclear steady-state localization. One potential model
would be that this region of VP22 interacts with and inhibits a
third partner in the VP22-ICP0 complex, be it cellular or viral,
that is involved normally in the ICP0 translocation pathway
from ND10s to the cytoplasm. Thus, it is noteworthy that this
VP22 mutant virus exhibits an ICP0 phenotype similar to that
of a point mutant of ICP0 (with a D199A mutation) described
by the Roizman laboratory. This mutant is unable to bind
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cyclin D3, a cellular factor that this group has characterized as
being involved in ICP0 translocation (26, 47, 48).
Taken together, these results may imply that VP22 is actively
involved in ICP0 translocation from the nucleus. While the
majority of full-length VP22 localizes to the cytoplasm of in-
fected cells as described above, a small population localizes to
discrete nuclear domains around the time that ICP0 begins to
leave the nucleus. We have previously characterized these
VP22-containing nuclear domains as being juxtaposed to
ICP0-containing ND10s (24). It is conceivable that this nuclear
population plays a role in directing ICP0 into its translocation
pathway by forming the complex identified in our pulldown
assays, with the N terminus dictating the formation of this
transport complex by interacting with a third partner. If VP22
is truly involved in ICP0 translocation, one question that re-
mains to be addressed concerns the cytoplasmic localization of
ICP0 in 22 mutant-infected cells. However, this situation is
similar to that of a ICP4 mutant virus infection in which ICP0
is efficiently transported, even in the absence of  and  gene
expression (31). Observations with the latter virus have led to
the proposal that an additional, post-	 gene is actively involved
in retaining ICP0 in the nucleus. Hence, as deletion of the
entire VP22 reading frame has more widespread effects than
simply an absence of ICP0 from virus particles (8, 9), it is
possible that overall ICP0 behavior is quite different in 22
mutant-infected cells and that any activity for nuclear retention
is not functional.
In summary, we have shown that ICP0 is a true virion com-
ponent that is assembled into the virion via a pathway that is
absolutely dependent on VP22. Furthermore, VP22 may play
an active role in determining the subcellular localization of
ICP0 during infection. The next stage of this work will be to
determine if virion-incorporated ICP0 has a function at early
times of infection. Such studies will be experimentally chal-
lenging but will provide invaluable information on the ever-
increasing complexity of ICP0 biology.
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